Cabiralizumab and nivolumab combination treatment fails to meet primary endpoint for use in pancreatic cancer

In a phase II RCT this combination treatment, with and without chemotherapy, did not show any meaningful benefit over standard of care. Cabiralizumab is a humanised monoclonal antibody directed against the TKR colony stimulating factor 1 receptor currently under investigation.